Gentium S.p.A.

Type: Public
On the web: http://www.gentium.it
Employees: 68
Employee growth: 11.5%

Gentium wants to soften the harsh effects of cancer treatment. The company seeks to minimize the damage done by cancer treatments such as chemotherapy and radiation therapy. The company's most advanced product candidates use defibrotide to relieve blood vessel disorders caused by such treatments, and could also have applications in additional inflammation and vascular disorders. Gentium also manufactures and sells active pharmaceutical ingredients, including heparin, an anticoagulant.

Key numbers for fiscal year ending December, 2011:
Sales: $32.1M
One year growth: (1.4%)
Net income: $3.6M
Income growth: (32.6%)

Officers:
Chairman and CEO: Khalid Islam
SVP and CFO: Biopharmaceuticals & Biotherapeutics Manufacturing

Competitors:
Bristol-Myers Squibb
Genzyme
Roche Italy